ScholarIQanswers from OpenAlex

Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage

PaperCitations, authors & open-access status

Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage have?

ScholarIQcitation count

Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage has 0 citations in the OpenAlex counts ScholarIQ stores.

When was Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage published?

ScholarIQyear

Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage has 2025 year in the ScholarIQ index.

What is the open-access status of Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage?

ScholarIQoa status

Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage has closed oa status in the ScholarIQ index.

What is the DOI of Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage?

ScholarIQdoi

The DOI for Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage is on the source record.

What is the PMID of Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage?

ScholarIQpmid

The PMID for Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage is on the source record.

What is the OpenAlex record for Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage?

ScholarIQopenalex

The OpenAlex for Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial